CHRS Stock: About Coherus BioScience, Inc.
CHRS or Coherus Biosciences Inc. is a biotechnology company developing biosimilar therapeutics. The company founded ten years ago and their main interests in the market are biosimilar treatment and immuno-oncology. Their business is by a majority located around United States and the company headquarter is in Redwood City, California.
CHRS Stock: Coherus BioSciences’ Price to Earnings Ratio
The P/E ratio or price to earnings ratio is a simple way to assess whether a stock is over or under valued and it is the most commonly used valuation measure. The price to earnings ratio helps investors determine the market value of a stock as compared to Coherus BioSciences’ earnings. The P/E ratio can be viewed as the number of years it takes for Coherus BioSciences to earn back the price you pay for the CHRS stock.
A high price to earnings ratio means that the stock’s price is high compared to earnings and possibly overvalued. On the contrary, a low price to earnings ratio indicates that the current stock price is low compared to earnings. The price to earnings ratio is calculated by taking the current CHRS stock price and dividing it by the most recent trailing 12 months earnings per share number. The data of the current and historical price to earnings ratio is updated every 20 minutes during market hours. It cannot be said to make sense to use price to earnings ratio alone to determine whether you should sell your stocks, yet it can be a practical guide to the company’s future prospects.
When deciding whether to buy, sell or hold the stock, you should know the current and historical daily price to earnings ratio of the CHRS stock. During the past 9 years, Coherus BioSciences’s highest price to earnings ratio was 18.93, the lowest was 0.00 and the median was 9.02.
CHRS Stock: Coherus BioSciences Inc Stock Forecast Predictions & Price Targets
Over the next 52 weeks, Coherus BioSciences Inc. has an average historically fallen by 7.5% based on the past 6 years of stock performance. Several analysts believe that Coherus BioSciences tends to keep its downward curve of economical state for the next couple of weeks. They therefore hold a negative evaluation of CHRS stock. Some analysts agree that it is hard to see the share price rising strongly in the near future under these circumstances.
Along with these Maxim Group published a “buy” rating and a $22.00 target price on the CHRS stock in a research note on Friday, May 7th. Another research note that published on the same day, Zacks Investment Research cut shares of Coherus BioSciences from a “hold” rating to a “sell” rating. H.C. Wainwright & Co. set a “buy” rating on CHRS stock by decreasing their price objective on stakes of Coherus BioScience from $29.00 to $26.00 on Thursday, May 13th.
Lastly, Coherus BioSciences’ price target decreased by equities researchers at Barclays from $28.00 to $24.00 in a research report issued on Monday, May 24th. Barclay’s price objective indicates a potential increase of 78.04% from the company’s previous close. To summarize these notes and more, according to the analysis that came from 5 Wall Street analysts in the past 3 months, Coherus BioSciences’ average price target determined as $24.86
This price target is the average of a high forecast of $30.00 and a low forecast of $18.00. Likewise, 9 analysts offering one year price forecasts for Coherus BioSciences have a median target of $25.00, with a high forecast of $ 35.00 and a low forecast of $16.00. Last of all, Coherus BioSciences currently has an average rating of “buy”.
This is not investment advice. You must do your own research and make your own decisions. We are not responsible for the problems that may arise from your investment.